Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phillip Fleshner

Showing results (91-100 of 111) with videos related to

Pageof 12
Sort By:
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Reduced expression of COVID-19 host receptor, <i>ACE2</i> is associated with small bowel inflammation, more severe disease, and response to anti-TNF therapy in Crohn's diseaseAlka A Potdar, Shishir Dube, Takeo Naito, et al.
Scientific Reports|November 29, 2017
CSA13 inhibits colitis-associated intestinal fibrosis via a formyl peptide receptor like-1 mediated HMG-CoA reductase pathwayChunlan Xu, Sally Ghali, Jiani Wang, et al.
Diseases of the Colon and Rectum|July 23, 2025
Improvement in Functional Outcomes Following Ileal Pouch-Anal Anastomosis: Results from the United States Ileal Pouch-Anal Anastomosis StudyJesse Zuckerman, Anthony de Buck van Overstraeten, Gil Y Melmed, et al.
Journal of Crohn'S & Colitis|December 9, 2017
Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's DiseaseAmy L Lightner, Nicholas P McKenna, Chung Sang Tse, et al.
Gastroenterology|November 8, 2020
Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel DiseaseAlka A Potdar, Shishir Dube, Takeo Naito, et al.
Diseases of the Colon and Rectum|February 16, 2005
Practice parameters for the management of hemorrhoids (revised)Peter Cataldo, C Neal Ellis, Sharon Gregorcyk, et al.
Diseases of the Colon and Rectum|April 27, 2004
Practice parameters for the surveillance and follow-up of patients with colon and rectal cancerThomas Anthony, Clifford Simmang, Neil Hyman, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 7, 2022
Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort StudySiddharth Singh, Jihoon Kim, Jiyu Luo, et al.
Inflammatory Bowel Diseases|February 4, 2014
Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patientsAdam Weizman, Brian Huang, Dror Berel, et al.
World Journal of Gastrointestinal Surgery|April 5, 2024
Pre-operative visceral adipose tissue radiodensity is a potentially novel prognostic biomarker for early endoscopic post-operative recurrence in Crohn's diseasePhillip Gu, Shishir Dube, Norman Gellada, et al.
Pageof 12

Showing results (91-100 of 111) with videos related to

Sort By:
Pageof 12
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Reduced expression of COVID-19 host receptor, <i>ACE2</i> is associated with small bowel inflammation, more severe disease, and response to anti-TNF therapy in Crohn's diseaseAlka A Potdar, Shishir Dube, Takeo Naito, et al.
Scientific Reports|November 29, 2017
CSA13 inhibits colitis-associated intestinal fibrosis via a formyl peptide receptor like-1 mediated HMG-CoA reductase pathwayChunlan Xu, Sally Ghali, Jiani Wang, et al.
Diseases of the Colon and Rectum|July 23, 2025
Improvement in Functional Outcomes Following Ileal Pouch-Anal Anastomosis: Results from the United States Ileal Pouch-Anal Anastomosis StudyJesse Zuckerman, Anthony de Buck van Overstraeten, Gil Y Melmed, et al.
Journal of Crohn'S & Colitis|December 9, 2017
Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's DiseaseAmy L Lightner, Nicholas P McKenna, Chung Sang Tse, et al.
Gastroenterology|November 8, 2020
Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel DiseaseAlka A Potdar, Shishir Dube, Takeo Naito, et al.
Diseases of the Colon and Rectum|February 16, 2005
Practice parameters for the management of hemorrhoids (revised)Peter Cataldo, C Neal Ellis, Sharon Gregorcyk, et al.
Diseases of the Colon and Rectum|April 27, 2004
Practice parameters for the surveillance and follow-up of patients with colon and rectal cancerThomas Anthony, Clifford Simmang, Neil Hyman, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 7, 2022
Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort StudySiddharth Singh, Jihoon Kim, Jiyu Luo, et al.
Inflammatory Bowel Diseases|February 4, 2014
Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patientsAdam Weizman, Brian Huang, Dror Berel, et al.
World Journal of Gastrointestinal Surgery|April 5, 2024
Pre-operative visceral adipose tissue radiodensity is a potentially novel prognostic biomarker for early endoscopic post-operative recurrence in Crohn's diseasePhillip Gu, Shishir Dube, Norman Gellada, et al.
Pageof 12